ERBB2 and breast carcinoma: In the study here, the finding that HER2 was found to be highly sensitive (high positive response detection rate) but not specific (low negative response detection rate) to response was in agreement with the findings from a previous molecular biomarker study5 where a statistically significant correlation was found between HER2 status and complete response in breast cancer patients receiving T-FAC chemotherapy.